Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2021 Financial Results on Thursday, March 31, 2022
Spero Therapeutics (Nasdaq: SPRO) will hold a conference call on March 31, 2022, at 4:30 p.m. ET to discuss its fourth quarter and full-year 2021 financial results and provide a business update.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Spero Therapeutics (Nasdaq: SPRO) will hold a conference call on March 31, 2022, at 4:30 p.m. ET to discuss its fourth quarter and full-year 2021 financial results and provide a business update. The call can be accessed via phone or a live audio webcast available on Spero's website. Spero focuses on creating novel treatments for multi-drug-resistant bacterial infections, with its lead candidate, tebipenem HBr, recently receiving FDA NDA acceptance. This investigational drug aims to address complicated urinary tract infections but is not yet approved.
Positive
- FDA accepted NDA for tebipenem HBr, advancing towards market approval.
Negative
- Tebipenem HBr is still investigational and not yet approved for the treatment of cUTI.
- No specific financial metrics are provided ahead of the earnings call, raising concerns about upcoming results.
Details
News Market Reaction – SPRO
The recorded move for SPRO in the trading session of this news was +0.24%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced that it will host a conference call and live audio webcast on Thursday, March 31, 2022, at 4:30 p.m. ET to report its fourth quarter and full-year 2021 financial results and provide an update on its business and pipeline.
To access the call, please dial 1-877-705-6003 (domestic) or 1-201-493-6725 (international) and refer to conference ID 13727002. The audio webcast can be accessed under “Events and Presentations” in the Investor and Media section of the Company’s website at www.sperotherapeutics.com. The archived webcast will also be available on Spero’s website for 30 days following the call.
About Spero Therapeutics
Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.
Spero Therapeutics’ lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is in development as the first oral carbapenem antibiotic for use in cUTI, including pyelonephritis. On January 3, 2022, Spero Therapeutics announced that the FDA had accepted its NDA for tebipenem HBr tablets.
Tebipenem HBr is an investigational drug in the United States and is currently not approved for the treatment of complicated urinary tract infection, including pyelonephritis.
Spero Therapeutics is also developing SPR720 as a novel oral therapy product candidate for the treatment of a rare, orphan pulmonary disease caused by non-tuberculous mycobacterial infections.
Spero Therapeutics also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is in development to treat MDR Gram-negative infections in the hospital setting.
For more information, visit https://sperotherapeutics.com.
Investor Relations Contact:
Ted Jenkins
Vice President, Investor Relations and Specialty Finance
Tjenkins@sperotherapeutics.com
(617) 798-4039
Media Contact:
Jacqueline Pomfret Kirby
Vice President, Corporate Affairs
Jkirby@sperotherapeutics.com
(617) 798-4074
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.